- Veracyte's (VCYT, Financial) Decipher Prostate Genomic Classifier data is now part of the NCI SEER database, enhancing research capabilities.
- The SEER database includes over 560,000 prostate cancer cases diagnosed from 2010 to 2018.
- The Decipher Prostate test is designed to aid treatment decisions through comprehensive genomic analysis.
Veracyte, Inc. (VCYT), a leader in cancer diagnostics, has announced the integration of its Decipher Prostate Genomic Classifier data into the National Cancer Institute's (NCI) SEER (Surveillance, Epidemiology, and End Results) Program's newly released specialized database. This strategic collaboration allows researchers to analyze Decipher Prostate test results alongside real-world patient outcomes, cancer characteristics, treatment protocols, and demographics, thereby advancing prostate cancer research significantly.
The SEER database linkage encompasses over 560,000 prostate cancer cases diagnosed between 2010 and 2018. The Decipher Prostate test, a 22-gene test developed using RNA whole-transcriptome analysis and machine learning, has been available for radical prostatectomy specimens since 2013 and biopsy tissue since 2016. Its inclusion in the SEER database reinforces Veracyte's commitment to building clinical evidence and advancing scientific understanding of cancer.
According to Philip Febbo, M.D., Veracyte's chief scientific officer and chief medical officer, the collaboration with the NCI SEER Program presents numerous opportunities for prostate cancer researchers and aims ultimately to benefit patients. This integration further strengthens Veracyte's position in cancer diagnostics, enhancing the clinical validation and market positioning of the Decipher Prostate test.
Veracyte continues to empower clinicians with high-value insights necessary for guiding and reassuring patients at critical moments in the cancer treatment process. The company's efforts are supported by its Veracyte Diagnostics Platform, which delivers high-performing cancer tests backed by a robust evidence-generation engine and bioinformatics capabilities.
